Kejun Nan
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Hepatology 19
- Hepatocellular Carcinoma Treatment and Prognosis 19
-
- MicroRNA in disease regulation 7
- Co-authors
- Tao Tian (14 shared papers)Hui Guo (16 shared papers)Zhiping Ruan (13 shared papers)Qiuping Liu (1 shared paper)Shuhong Zhao (1 shared paper)Mo‐qi Lv (1 shared paper)Dang‐xia Zhou (1 shared paper)Xuan Liang (7 shared papers)
- Journals
- Cancer Management and Research (3 papers)Oncotarget (3 papers)World Journal of Gastroenterology (3 papers)Medicine (3 papers)The International Journal of Biochemistry & Cell Biology (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Kejun Nan
59 papers receiving 2.2k citations
Kejun Nan's Hit Papers
Peers
Comparison fields: 5 of 74
- Cancer Research 448
- Hepatology 262
- Oncology 432
- Pulmonary and Respiratory Medicine 386
- Molecular Biology 633
Countries citing papers authored by Kejun Nan
This map shows the geographic impact of Kejun Nan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kejun Nan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kejun Nan more than expected).
Fields of papers citing papers by Kejun Nan
This network shows the impact of papers produced by Kejun Nan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kejun Nan. The network helps show where Kejun Nan may publish in the future.
Co-authors
The 25 scholars most cited alongside Kejun Nan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 503 |
| 2 | 2017 | 219 | |
| 3 | 2017 | 139 | |
| 4 | 2015 | 77 | |
| 5 | 2017 | 60 | |
| 6 | 2016 | 54 | |
| 7 | 2017 | 52 | |
| 8 | 2014 | 50 | |
| 9 | 2018 | 48 | |
| 10 | 2017 | 47 | |
| 11 | 2018 | 47 | |
| 12 | 2013 | 46 | |
| 13 | 2013 | 44 | |
| 14 | 2012 | 42 | |
| 15 | 2017 | 37 | |
| 16 | 2011 | 36 | |
| 17 | 2016 | 36 | |
| 18 | 2016 | 36 | |
| 19 | 2017 | 35 | |
| 20 | 2015 | 32 |
About Kejun Nan
Kejun Nan is a scholar working on Hepatology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 59 papers that have together received 2.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (19 papers), MicroRNA in disease regulation (7 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer-related Molecular Pathways (4 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), Gastric Cancer Management and Outcomes (3 papers), Cervical Cancer and HPV Research (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Cancer Research (448 citations), Hepatology (262 citations), Oncology (432 citations), Pulmonary and Respiratory Medicine (386 citations) and Molecular Biology (633 citations). Kejun Nan has collaborated with scholars based in China and United States. Frequent co-authors include Tao Tian, Hui Guo, Zhiping Ruan, Qiuping Liu, Shuhong Zhao, Mo‐qi Lv, Dang‐xia Zhou, Xuan Liang, Lili Jiang and Mincong Wang. Their work appears in journals such as Cancer Management and Research, Oncotarget, World Journal of Gastroenterology, Medicine and The International Journal of Biochemistry & Cell Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.